The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Baĭdina T.V.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera", Perm'

Trushnikova T.N.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera", Perm'

Danilova M.A.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera" Minzdrava RF, Perm'

Interferon-induced depression and peripheral blood serotonin in patients with multiple sclerosis

Authors:

Baĭdina T.V., Trushnikova T.N., Danilova M.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8‑2): 77‑81

DOI: 10.17116/jnevro201811808277

Views: 2997

Downloaded: 88

Download PDF (RU)
Contact the author
Table of contents

INTERFERON-INDUCED DEPRESSION AND PERIPHERAL BLOOD SEROTONIN IN PATIENTS WITH MULTIPLE SCLEROSIS
INTERFERON-INDUCED DEPRESSION AND PERIPHERAL BLOOD SEROTONIN IN PATIENTS WITH MULTIPLE SCLEROSIS

To cite this article:

Baĭdina TV, Trushnikova TN, Danilova MA. Interferon-induced depression and peripheral blood serotonin in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8‑2):77‑81. (In Russ.)
https://doi.org/10.17116/jnevro201811808277

 
Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Close metadata
Recommended articles:
Pathogenetic basis of modern approaches to the therapy of sleep diso­rders in the clinic of depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):69-74
Features of the clinical picture of affe­ctive diso­rders in women during the meno­pausal transition and early postmenopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):75-79
Long-term effi­cacy and safety of divo­zilimab during 2-year treatment of multiple scle­rosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):86-96
A case of COVID-associated ence­phalopathy in a patient with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):159-163
Opti­cal cohe­rence tomo­graphy angiography in the diagnosis of multiple scle­rosis. Russian Annals of Ophthalmology. 2024;(2):63-70
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30
A role of cere­brovascular diseases in the progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):53-57
Posttraumatic stress diso­rder clinical guidelines and treatment standards: focus on the symptoms of the psychophysiological arousal. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):58-68
Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137
Oral seda­tion in pediatric outpatient dentistry. Stomatology. 2024;(3):42-49

Objective. To study the dynamics of anxiety-depressive disorders and peripheral blood serotonin in patients with multiple sclerosis (MS) during interferon-ß (IFN-ß) therapy. Material and methods. The level of anxiety and depression in 227 MS patients was measured by psychometric testing at baseline and during treatment. The concentration of serotonin in serum of patients was determined by enzyme immunoassay. Results. The presence of emotional disorders in patients with MS was confirmed. Their relationship with personality characteristics of the patient, the course of the disease and social status was shown. The level of humoral serotonin was lower in patients with MS. The relationship between the serotonergic system deficiency in patients with MS and anxiety disorders was shown. Interferon-induced depression was not associated with serotonin metabolism. It is a multifactor condition influenced by the patient’s initial emotional level, personality characteristics, psychological reaction to therapy and the unfavorable dynamics of the disease. Conclusion. IFN-β does not appear to induce depression in MS patients.

Keywords:

multiple sclerosis
IFN-β
anxiety
depression
serotonin

Authors:

Baĭdina T.V.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera", Perm'

Trushnikova T.N.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera", Perm'

Danilova M.A.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera" Minzdrava RF, Perm'

List of references:

  1. Kesselring J, Klement U. Cognitive and affective disturbances in multiple sclerosis. J Neurol. 2001;248(3):180-183. https://doi.org/10.1007/s004150170223
  2. Baidina TV, Kuklina EM, Trushnikova TN, Pichkaleva YuA, Sursyakova NV, Danchenko IYu, Medvedeva EL, Foteeva AV. Pathogenetic and clinical peculiarities of disseminated sclerosis. Perm Med J. 2016;33(4):17-22. (In Russ.) https://elibrary.ru/item.asp?id=26685037
  3. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7(9):942-947. https://doi.org/10.1038/sj.mp.4001119
  4. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. 2000;18(11):2316-2326. https://doi.org/10.1200/jco.2000.18.11.2316
  5. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655-661. https://doi.org/10.1212/wnl.43.4.655
  6. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277-1285. https://doi.org/10.1212/wnl.45.7.1277
  7. Goeb JL, Even C, Nicolas G, Gohier B, Dubas F, Garré JB. Psychiatric side effects of interferon-beta in multiple sclerosis. Eur Psychiatry. 2006;21(3):186-193. https://doi.org/10.1016/j.eurpsy.2005.09.013
  8. Patten SB, Williams JV, Metz LM. Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Mult Scler. 2008;14(3):406-411. https://doi.org/10.1177/1352458507082942
  9. Zephir H, Seze J, Stojkovic T, Delisse B. Multiple sclerosis and depression: influence of interferon beta therapy. Mult Sclerosis J. 2003;9(3):284-288. https://doi.org/10.1191/1352458503ms915oa
  10. Arnett PA. Longitudinal course of depression symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(5):606-610. https://doi.org/10.1136/jnnp.2004.047712
  11. Goeb JL, Cailleau A, Laine P. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol. 2003;26(1):5-7. https://doi.org/10.1097/00002826-200301000-00002
  12. Pandya R, Patten S. Depression in multiple sclerosis associated with interferon beta-1a (Rebif). Can J Psychiatry. 2002;47(7):686. https://doi.org/10.1177/070674370204700720
  13. de Long HJL, Kingwell E, Shirani A, Tervaert CJW, Hupperts R, Zhao Y, Zhu F, Evans C, van der Kop ML, Traboulsee A, Gustafson P, Petkau J, Marrie RA, Tremlett H. Evaluating the safety of β-interferons in MS: A series of nested case-control studies. Neurology. 2017;88(24):2310-2320. https://doi.org/10.1212/wnl.0000000000004037
  14. Akintseva YV, Baidina TV. Platelet serotonin in patients with multiple sclerosis. Vrach-aspirant. 2011;48 (5, 4):614-619. (In Russ.)
  15. Myint AM, Schwarz MJ, Steinbusch HW, Leonard BE. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis. 2008;24(1):55-68. https://doi.org/10.1007/s11011-008-9114-5
  16. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol. 2000;18(11):2316-2326. https://doi.org/10.1200/jco.2000.18.11.2316
  17. Mirsky MM, Marrie RA, Rae-Grant A. Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy. Int J MS Care. 2016;18(6):305-310. https://doi.org/10.7224/1537-2073.2016-056
  18. Schippling S, O’Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, Cook S, Filippi M, Hartung H, Comi G, Jeffery DR, Kappos L, Goodin DS, Arnason B. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. 2016;263(7):1418-1426. https://doi.org/10.1007/s00415-016-8146-8
  19. Kirzinger SS, Jones J, Siegwald A, Crush AB. Relationship between disease-modifying therapy and depression in multiple sclerosis. Int J MS Care. 2013;15(3):107-112. https://doi.org/10.7224/1537-2073.2012-036
  20. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. COGIMUS Study Group. Mult Scler. 2011;17(8):991-1001. https://doi.org/10.1177/1352458511401943
  21. Patten SB. What is the best approach to treating in-terf eron-induced depression in people with multiple sclerosis? J Neurosci. 2001;26:66-69.
  22. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol. 2000;18(11):2316-2326. https://doi.org/10.1200/jco.2000.18.11.2316

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.